Category - Developments

Developments

IntelGenx, Tilray in definitive partnership for cannabis VersaFilm products

IntelGenx (TSXV:IGX; OTCQX:IGXT) and Tilray (NASDAQ:TLRY) signed a definitive license, development and supply agreement to co-develop and commercialize oral film VersaFilm products infused with adult-use and medical...

November 7, 2018

Developments

Constellation Brands closes $5-billion investment in Canopy Growth

Constellation Brands (NYSE:STZ) closed its $5-billion (Canadian) investment in Canopy Growth (TSX:WEED; NYSE:CGC) following approval by Canopy shareholders and all regulatory agencies, including the Canadian government...

November 1, 2018

Developments

elminda, Villages Health joint study receives Erickson Foundation aging award

A joint research project between closely-held elminda of Israel and The Villages Health of Florida will receive the prestigious Erickson Foundation Award for Excellence in Aging Research at the upcoming 2018 American...

November 1, 2018

Developments

Scientus Pharma updates buccal cannabis spray development collaboration with Generex

Closely-held Scientus Pharma updated its collaboration with Generex Biotechnology (OTCQB:GNBT) to co-develop products for the delivery of cannabinoids via the buccal mucosa, or inner lining of the mouth. Having recently...

October 31, 2018

Developments

IntelGenx partner receives marketing clearance for RIZAPORT in Spain

IntelGenx’s (TSXV:IGX; OTCQX:IGXT) commercialization partner, Groupo Juste, which is now part of Exceltis Healthcare, has received national marketing authorization for RIZAPORT 10 mg from the Spanish Agency of Medicines...

October 31, 2018

Developments

Physicians Endoscopy adds three GI ambulatory partnerships

Closely-held Physicians Endoscopy (PE) announced the addition of three GI ambulatory surgery center (ASC) partnerships that were finalized between July and September of 2018. The partnerships increase PE’s...

October 30, 2018

Developments

ContraVir Pharma completes dosing in CRV431 drug-drug interaction study

ContraVir Pharmaceuticals (NASDAQ:CTRV) completed dosing of the last cohort of healthy subjects for its CRV431 drug-drug interaction (DDI) study. The single-dose crossover study evaluated subjects co-treated with...

October 30, 2018

Developments

Knight Therapeutics launches Titan Pharma’s Probuphine in Canada

Knight Therapeutics (TSX:GUD) announced the Canadian launch of Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine subdermal implant of buprenorphine hydrochloride for the management of opioid dependence in patients...

October 29, 2018

Developments

Lobo Cube DNA testing device for safer cannabis use gaining major media attention

An Oct. 26 article on the Washington Post web site discusses job openings in Canada’s legalized cannabis sector, highlighting an Ontario government policy advisor who left his job to join Lobo Genetics as its director...

October 26, 2018

Developments

Mati Therapeutics expands IP portfolio to 114 patents in 19 patent families

Closely-held Mati Therapeutics’ international patent portfolio has grown to 114 issued patents, including a recently granted U.S. patent, which covers a drug delivery system for administering an ophthalmic drug through...

October 24, 2018

Category - Developments

Subscribe